Key Points {#FPar1}
==========

Anti-tumor necrosis factor and anti-interleukin (IL)-12/23 have been shown to be effective in treating patients with moderate to severe psoriasis.Anti-IL-17 drugs showed an equal or greater chance of leading patients to a 75% improvement when compared with other biologics/small molecule inhibitors.Ixekizumab showed higher efficacy among FDA-approved drugs when a 90 or 100% improvement over the baseline Psoriasis Area and Severity Index was analyzed.

Introduction {#Sec1}
============

Psoriasis is a chronic, immune-mediated inflammatory disease, where an intricate immune process, mainly driven by the T-helper (Th) 1/Th17 branch of the immune system, leads to persistent inflammation \[[@CR1]--[@CR3]\].

The treatment of psoriasis has been revolutionized by the introduction of biologic and small molecule inhibitor targeted therapy. Several of these therapies have been released and are available for general use, such as infliximab \[[@CR4]\], adalimumab \[[@CR5]\], ustekinumab \[[@CR6]\], apremilast \[[@CR7]\], etanercept \[[@CR8]\], ixekizumab \[[@CR9]\], and secukinumab \[[@CR10]\], while others are in phase II or later trials, e.g. brodalumab \[[@CR11]\], guselkumab \[[@CR12]\], certolizumab pegol \[[@CR13]\], and tofacitinib \[[@CR14]\]. On the other hand, studies on the efficacy of briakinumab were halted because of safety concerns during phase III trials \[[@CR15]\].

Schmitt et al. \[[@CR16]\] recently carried out a meta-analysis that included studies that evaluated systemic treatments for psoriasis (biologics or not) published before October 2012. This review did not include anti-IL-17 drugs, and infliximab 5 mg/kg was superior to ustekinumab, adalimumab and etanercept. Xiong et al. published a systematic review that only included secukinumab, one of the anti-IL-17 biologic drugs, and concluded that anti-IL-17 drugs would be more efficacious than currently available biologics \[[@CR17]\]. Also in 2015, Chen et al. performed a meta-analysis comparing only anti-IL-17 drugs, and reported a greater chance of response of brodalumab 140 mg, followed by ixekizumab 25 mg and secukinumab 150 mg \[[@CR18]\].

As new drugs have emerged in the last few years \[[@CR9], [@CR11], [@CR13], [@CR14]\], it is important to update previous reviews to provide the best evidence on the efficacy of recent treatments for psoriasis. This study aimed to systematically review the evidence on the efficacy of biologic and small molecule inhibitor drugs for the treatment of moderate to severe psoriasis

Methods {#Sec2}
=======

This systematic review and meta-analysis was conducted using the recommendations of the Cochrane Initiative, and reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR19]\].

Search Strategy/Databases Searched/Eligibility Criteria {#Sec3}
-------------------------------------------------------

The research question ("What is the efficacy, measured by the improvement of 75% over baseline Psoriasis Area and Severity Index (PASI), of biologic and small molecule inhibitor drugs for moderate to severe psoriasis patients when compared to placebo?") was formulated using the PICO method (Population, Intervention, Comparator, Outcome). The EMBASE, PUBMED, LILACS, Web of Science and ClinicalTrials.org databases were searched for double-blind, randomized, placebo-controlled clinical trials (RCTs) published to 21 July 2016. Search strategies involved use of the terms 'psoriasis AND (abatacept OR apremilast OR CC-10004 OR adalimumab OR D2E7 OR briakinumab OR ABT-480 OR brodalumab OR certolizumab OR etanercept OR TNF Fc OR fezakizumab OR golimumab OR guselkumab OR CNTO1959 OR infliximab OR ixekizumab OR secukinumab OR Ly-2439821 OR sifalimumab OR siplizumab OR tasocitinib OR tofacitinib OR ustekinumab OR CNTO-1275 OR AbGn-168 OR RG-4934 OR APG-2305 OR MK-3222)'. Studies published online or in print, or studies in press were reviewed. Although we considered all languages eligible for the review, only studies published in English were found to be relevant.

Initially, duplicate studies were excluded and two researchers (AVEC and RPD) independently reviewed the titles and abstracts to exclude those studies that were clearly irrelevant. The reviewers then evaluated the full text of the remaining manuscripts and relevant articles were identified. Disagreements were solved by consensus. Randomized clinical trials were eligible for inclusion in the present review if they fulfilled the following criteria: human-based, double-blind, randomized, placebo-controlled clinical trials that evaluated adult patients and used the Psoriasis Area and Severity Index (PASI) as a measurement for psoriasis severity. Phase II studies were only included if the studied drugs or doses were identified in further phase III studies, or if drugs or doses were already approved by the US FDA. In the case of studies with multiple study arms, including approved and non-approved drugs or doses, only the arms containing approved drugs/doses were included in the meta-analysis. Head-to-head studies without a placebo arm were excluded from the analysis, and studies that evaluated the improvement of psoriatic arthritis as a primary outcome were also excluded. The reference lists of the articles included in the review were searched for additional studies.

The primary efficacy outcome was the number of patients who experienced a 75% improvement in disease status, measured by the PASI (PASI 75), at the time of the primary efficacy assessment. Secondary outcomes were 90% improvement (PASI 90) and 100% improvement (PASI 100) in disease status.

Data Extraction {#Sec4}
---------------

Using a standardized protocol \[[@CR20]\] entirely based on the Cochrane handbook for systematic reviews and interventions, reviewers extracted the following items from each study: authors; year of publication; intervention and comparator; total number of patients randomized; trial duration; mean disease duration; mean age of patients; mean baseline PASI; number of patients achieving PASI 75, 90 and 100; and prior use of biologic or concomitant medications. Effect estimates were extracted with 95% confidence intervals (CI). Any disagreement was also solved by consensus. It was decided not to use any quality assessment of the studies (i.e. JADAD), and to evaluate its impact on the estimated pooled effect using meta-regression/sensitivity analysis. Data regarding randomization, blinding, and complete reporting of the study results were also extracted to evaluate the risk of bias \[[@CR20]\].

Statistical Analysis {#Sec5}
--------------------

Effect measures were reported as the pooled risk difference (RD), and an RD \>0 denoted that those subjects who received the 'new drug' showed a higher risk of presenting the outcome. The overall pooled effect of any treatment versus placebo was estimated by running a separate analysis, with all treatment patients gathered in one group and all placebo patients in another group, to avoid the unit-of-analysis error. The number needed to treat (NNT) was also calculated.

Heterogeneity among studies was assessed using the Q-test and *I* ^2^, and a random-effects model was used. Sensitivity analysis was performed excluding phase II studies when heterogeneity was found to be \>50%. A funnel plot and Egger's test were used to investigate publication bias. We performed meta-regression to assess the influence of mean baseline PASI, previous use of biologics, and duration of the disease on the heterogeneity among studies.

Meta-analysis using data extracted from the studies was performed using STATA v.14 software for Mac (StataCorp LP, College Station, TX, USA). Forest plots, funnel plots, and risk of bias assessment graphs were developed using Review Manager Version 5.3. (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

Results {#Sec6}
=======

Overall, 9544 records were identified through a database search, with 5 additional records identified through a search of the bibliographical references of published meta-analyses. After removing duplicates, 6513 records were screened and 6181 were excluded (3822 were not RCTs, 2039 did not pertain to psoriasis, 122 pertained to drugs not encompassed in this review, and 198 were additional duplicates).

Among the 332 articles selected for full-text review, 292 were excluded for the following reasons: 201 were not RCTs, 16 were RCTs that did not use placebo as the comparator, 45 due to the lack of PASI as the primary outcome, 5 were studies in the pediatric population, 4 were phase II studies without further confirmatory phase III studies, 8 were studies with doses not approved by the FDA, 9 pertained to psoriatic arthritis, and 4 were additional duplicates (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1PRISMA statement diagram for database searches for meta-analysis of the efficacy of biologics and small molecule inhibitors for psoriasis. *PRISMA* Preferred Reporting Items for Systematic Reviews and Meta-Analyses, *RCTs* randomized controlled trials, *PASI* Psoriasis Area and Severity Index

A total of 40 studies \[[@CR4], [@CR5], [@CR7]--[@CR9], [@CR11], [@CR14], [@CR21]--[@CR53]\] were included in the meta-analysis, providing 56 comparisons of 11 different interventions. In total, 22,884 patients were evaluated. The medications studied were adalimumab, apremilast, brodalumab, etanercept, infliximab, ixekizumab, secukinumab, tofacitinib and ustekinumab. Of the 40 studies included in the meta-analysis, 6 used a 10-week endpoint, 6 used a 16-week endpoint, and 28 used a 12-week endpoint. Primary endpoints for outcomes assessment were correlated with the induction period of the drugs and can be considered short-term therapy. All studies shared similar inclusion criteria and baseline characteristics (Table [1](#Tab1){ref-type="table"}). Risk of bias assessment showed that high risk of bias was low among the studies (Online Resource 1 and 2).Table 1Clinical trial identification and summary categorized by drug^a^DrugAuthor, yearIntervention/comparatorNo. of patients randomized (total patients)Total trial duration (weeks)Mean disease duration (years)Mean age of patientsMean Baseline PASIPrimary outcome measure/primary endpointAdalimumabAsahina, 2010 \[[@CR22]\]Adalimumab sc (40 mg EOW)^c^38 (169)2414.247.825.4PASI 75/wk 16Adalimumab sc (80 mg wk 0 + 40 mg EOW starting wk 1)43 (169)241444.230.2PASI 75/wk 16Adalimumab sc (80 mg EOW)^c^42 (169)2411.643.528.2PASI 75/wk 16Placebo46 (169)2415.543.929.1PASI 75/wk 16Gordon, 2006 \[[@CR5]\]Adalimumab 40 mg sc (80 mg wk 0 + 40 mg EOW starting week 1)46 (148)60214616.7PASI 75/wk 12Adalimumab 40 mg sc (80 mg wk 0 and 1 + 40 mg/wk starting wk 2)^c^50 (148)60184414.5PASI 75/wk 12Adalimumab 40 mg sc (80 mg wk 0 and 1 + 40 mg/wk starting wk 2)^c^50 (148)60184414.5PASI 75/wk 12Placebo52 (148)60194316PASI 75/wk 12Gordon 2015 \[[@CR48]\]Guselkumab 200 mg sc (wk 0, 4 and every 12 weeks)^c^42 (293)5219.44619.4PASI 75/wk 16Guselkumab 100 mg sc (every 8 weeks)^d^42 (293)5218.341.520.4PASI 75/wk 16Guselkumab 50 mg sc (wk 0, 4 and every 12 weeks)^c^42 (293)521844.522.3PASI 75/wk 16Guselkumab 15 mg sc (every 8 weeks)^c^41 (293)5217.34521.5PASI 75/wk 16Guselkumab 5 mg sc (wk 0, 4 and every 12 weeks)^c^41 (293)5219.54320.9PASI 75/wk 16Adalimumab sc (80 mg wk 0 and 1, then EOW)43 (293)5219.35020,2PASI 75/wk 16Placebo42 (293)521846.521.8PASI 75/wk 16Menter, 2008 \[[@CR32]\]Adalimumab 40 mg sc (80 mg wk 0 and 40 mg EOW starting week 1)814 (1212)5218.144.119PASI 75/wk 16Placebo398 (1212)5218.445.418.8PASI 75/wk 16Saurat, 2007 \[[@CR39]\]Adalimumab 40 mg sc (80 mg wk 0 + 40 mg EOW starting wk 1)108 (271)1617.942.920.2PASI 75/wk 16Methotrexate oral (7.5 mg until 25 mg/wk)^c^110 (271)1618.941.619.4PASI 75/wk 16Placebo53 (271)1618.840.719.2PASI 75/wk 16ApremilastPapp, 2012 \[[@CR7]\]Apremilast 10 mg orally bid^c^89 (352)241844.418.1PASI 75/wk 16Apremilast 20 mg orally bid^c^87 (352)2419.244.618.5PASI 75/wk 16Apremilast 3 0 mg orally bid88 (352)2419.244.119.1PASI 75/wk 16Placebo88 (352)2419.644.118.1PASI 75/wk 16Papp, 2015 \[[@CR35]\]Apremilast 30 mg bid562 (844)5219.845.818.7PASI 75/wk 16Placebo282 (844)5218.746.519.4PASI 75/wk 16BrodalumabLebwohl, 2015\
Amagine2 \[[@CR21]\]Brodalumab 210 mg sc EOW612 (1831)52194518.6PASI 75/wk 12Brodalumab 140 mg sc EOW610 (1831)52194518.9PASI 75/wk 12Ustekinumab300 (1831)52194518.9PASI 75/wk 12Placebo309 (1831)52184418.6PASI 75/wk 12Lebwohl, 2015\
Amagine3 \[[@CR21]\]Brodalumab 210 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)624 (1881)52184518,7PASI 75/wk 12Brodalumab 140 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)629 (1881)52174518.1PASI 75/wk 12Ustekinumab313 (1881)52184518.7PASI 75/wk 12Placebo315 (1881)52184419PASI 75/wk 12Papp, 2012 \[[@CR11]\]Brodalumab 70 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)^c^39 (198)1220.742.118.8PASI 75/wk 12Brodalumab 140 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)39 (198)1219.24419.4PASI 75/wk 12Brodalumab 210 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)40 (198)1217.142.120.6PASI 75/wk 12Brodalumab 280 mg sc monthly^c^42 (198)1219.342.317.9PASI 75/wk 12Placebo38 (198)1218.341.818.9PASI 75/wk 12EtanerceptBachelez, 2015 \[[@CR45]\]Tofacitinib 5 mg bid330 (1106)12164421PASI 75/wk 12Tofacitinib 10 mg bid332 (1106)12174421PASI 75/wk 12Etanercept 100 mg/wk336 (1106)12184219.4PASI 75/wk 12Placebo108 (1106)12174619.5PASI 75/wk 12Bagel, 2012 \[[@CR23]\]Etanercept sc (100 mg/wk)62 (124)2417.53915.5PASI 75/wk 12Placebo62 (124)2411.94215.2PASI 75/wk 12Gottlieb, 2003 \[[@CR26]\]Etanercept sc (50 mg/wk)57 (112)242348.217.8PASI 75/wk 12Placebo55 (112)242046.519.5PASI 75/wk 12Gottlieb, 2011 \[[@CR49]\]Etanercept sc (100 mg/wk)141 (347)121743.119.4PASI 75/wk 12Briakinumab 200 mg sc (wks 0 and 4 then 100 mg wk 8)138 (347)1216.143.618.4PASI 75/wk 12Placebo68 (347)1219.14418.5PASI 75/wk 12Griffiths, 2015\
 Uncover-2 \[[@CR46]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^347 (1224)12184519PASI 75/wk 12Ixekizumab (160 mg wk 0 and 80 mg every 2 wks)351 (1224)12194520PASI 75/wk 12Etanercept (100 mg/wk)358 (1224)12194519PASI 75/wk 12Placebo168 (1224)12194521PASI 75/wk 12Griffiths, 2015\
 Uncover-3 \[[@CR46]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^385 (1346)12184621PASI 75/wk 12Ixekizumab (160 mg wk 0 and 80 mg every 2 wks)386 (1346)12184621PASI 75/wk 12Etanercept (100 mg/wk)382 (1346)12184621PASI 75/wk 12Placebo193 (1346)12184621PASI 75/wk 12Langley, 2014\
 Fixture \[[@CR29]\]Secukinumab 300 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)327 (1306)5215.844.523.9PASI 75/wk 12Secukinumab 150 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)^c^327 (1306)5217.345.423.7PASI 75/wk 12Etanercept sc (100 mg/wk)326 (1306)5216.443.823.2PASI 75/wk 12Placebo326 (1306)5216.644.124.1PASI 75/wk 12Leonardi, 2003 \[[@CR31]\]Etanercept sc (25 mg/wk)^c^160 (652)2419.344.418.2PASI 75/wk 12Etanercept sc (50 mg/wk)162 (652)2418.545.418.5PASI 75/wk 12Etanercept sc (100 mg/wk)164 (652)2418.644.818.4PASI 75/wk 12Placebo166 (652)2418.445.618.3PASI 75/wk 12Mease, 2000 \[[@CR8]\]Etanercept sc (50 mg/wk)19 (38)12194610.1PASI 75/wk 12Placebo19 (38)1217.543.56.0PASI 75/wk 12Papp, 2005 \[[@CR50]\]Etanercept sc (50 mg/wk)204 (611)2421.54616.9PASI 75/wk 12Etanercept sc (100 mg/wk)203 (611)2418.144.516.1PASI 75/wk 12Placebo204 (611)2417.54416PASI 75/wk 12Strober, 2011 \[[@CR51]\]Etanercept sc (100 mg/wk)139 (350)1215.245.218.5PASI 75/wk 12Briakinumab 200 mg sc (wks 0 and 4, then 100 mg wk 8)139 (350)1216.344.919.4PASI 75/wk 12Placebo72 (350)1215.54518.3PASI 75/wk 12Tyring, 2007 \[[@CR42]\]Etanercept sc (100 mg/wk311 (618)9620.245.818.3PASI 75/wk 12Placebo307 (618)9619.745.518.1PASI 75/wk 12Van der Kerkhof, 2008 \[[@CR28]\]Etanercept sc (50 mg/week)96 (142)2419.345.921.4PASI 75/wk 12Placebo46 (142)2417.343.621PASI 75/wk 12InfliximabChaudari, 2001 \[[@CR4]\]Infliximab 5 mg/kg iv (wks 0, 2 and 6)11 (33)10ND5122.1PASI 75/wk 10Infliximab 10 mg/kg iv (wks 0, 2 and 6)^c^11 (33)10ND3526.6PASI 75/wk 10Placebo11 (33)10ND4520.3PASI 75/wk 10Gottlieb, 2004 \[[@CR47]\]Infliximab 3 mg/kg iv (wks 0, 2 and 6)99 (249)30184520PASI 75/wk 10Infliximab 5 mg/kg iv (wks 0, 2 and 6)99 (249)30164420PASI 75/wk 10Placebo51 (249)30164518PASI 75/wk 10Menter, 2007 \[[@CR33]\]Infliximab 3 mg iv (wks 0, 2 and 6)313 (835)5018.143.420.1PASI 75/wk 10Infliximab 5 mg iv (wks 0, 2 and 6)314 (835)5019.144.520.4PASI 75/wk 10Placebo208 (835)5017.844.419.8PASI 75/wk 10Reich, 2005 \[[@CR38]\]Infliximab 5 mg iv (wks 0, 2, 6, and then every 8 wks)301 (317)5019.142.622.9PASI 75/wk 10Placebo77 (317)5017.343.822.8PASI 75/wk 10Torri, 2010 \[[@CR40]\]Infliximab 5 mk/kg iv (wks 0, 2, 6 and 8)35 (54)7814.246.931.9PASI 75/wk 10Placebo19 (54)7811.143.333.1PASI 75/wk 10Yang, 2012 \[[@CR43]\]Infliximab 5 mk/kg iv (wks 0, 2, 6, 14 and 22)84 (129)261640.123.9PASI 75/wk 10Placebo45 (129)261639.425.3PASI 75/wk 10IxekizumabGriffiths, 2015\
 Uncover-2 \[[@CR46]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^347 (1224)12184519PASI 75/wk 12Ixekizumab (160 mg wk 0 and 80 mg every 2 wks)351 (1224)12194520PASI 75/wk 12Etanercept (100 mg/wk)358 (1224)12194519PASI 75/wk 12Placebo168 (1224)12194521PASI 75/wk 12Griffiths, 2015\
 Uncover-3 \[[@CR46]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^385 (1346)12184621PASI 75/wk 12Ixekizumab (160 mg wk 0 and 80 mg every 2 wks)386 (1346)12184621PASI 75/wk 12Etanercept (100 mg/wk)382 (1346)12184621PASI 75/wk 12Placebo193 (1346)12184621PASI 75/wk 12Gordon, 2016\
 Uncover-1 \[[@CR53]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^433 (1296)12194620PASI 75/wk 12Ixekizumab (160 mg wk 0 and 80 mg every 2 wks)433 (1296)12204520PASI 75/wk 12Placebo431 (1296)12204620PASI 75/wk 12SecukinumabBlauvelt, 2014 \[[@CR24]\]Secukinumab 300 mg sc (wks 0, 1, 2, 3, 4, 8)59 (177)121845.120.7PASI 75/wk 12Secukinumab 150 mg sc (wks 0, 1, 2, 3, 4, 8)^c^59 (177)1220.44620.5PASI 75/wk 12Placebo59 (177)1220.246.521.1PASI 75/wk 12Langley, 2014\
 Erasure \[[@CR29]\]Secukinumab 150 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)^c^245 (738)5217.544.922.3PASI 75/wk 12Secukinumab  300 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)^c^327 (1306)5217.345.423.7PASI 75/wk 12Placebo248 (738)5217.345.421.4PASI 75/wk 12Langley, 2014\
 Fixture \[[@CR29]\]Secukinumab 300 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)327 (1306)5215.844.523.9PASI 75/wk 12Secukinumab 150 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)^c^327 (1306)5217.345.423.7PASI 75/wk 12Etanercept sc (100 mg/wk)326 (1306)5216.443.823.2PASI 75/wk 12Placebo326 (1306)5216.644.124.1PASI 75/wk 12Paul, 2014 \[[@CR37]\]Secukinumab 150 mg sc (wks 0, 1, 2, 3, 4, 8)61 (182)5220.643.922PASI 75/wk 12Secukinumab 300 mg sc (wks 0, 1, 2, 3, 4, 8)60 (182)522146.618.9PASI 75/wk 12Placebo61 (182)5219.843.719.4PASI 75/wk 12TofacitinibBachelez \[[@CR45]\]Tofacitinib 5 mg bid330 (1106)12164421PASI 75/wk 12Tofacitinib 10 mg bid332 (1106)12174421PASI 75/wk 12Etanercept 100 mg/wk336 (1106)12184219.4PASI 75/wk 12Placebo108 (1106)12174619.5PASI 75/wk 12Papp, 2012 \[[@CR14]\]Tofacitinib 2 mg orally bid49 (197)1616.52921.5PASI 75/wk 12Tofacitinib 5 mg orally bid49 (197)1616.42921.2PASI 75/wk 12Tofacitinib 15 mg orally bid49 (197)1616.93122.6PASI 75/wk 12Placebo50 (197)1617.23621.5PASI 75/wk 12Papp, 2015\
 OPT1 \[[@CR52]\]Tofacitinib 5 mg orally bid363 (900)16164619.5PASI 75/wk 12Tofacitinib 10 mg bid360 (900)1616.94620.4PASI 75/wk12Placebo177 (900)1615.74519.8PASI 75/wk 12Papp, 2015\
 OPT2 \[[@CR52]\]Tofacitinib 5 mg orally bid382 (959)1615.24720.7PASI 75/wk 12Tofacitinib 10 mg bid381 (959)1615.24419.3PASI 75/wk 12Placebo196 (959)1616.44520.1PASI 75/wk 12UstekinumabIgarashi, 2011 \[[@CR27]\]Ustekinumab 45 mg (wks 0, 4 and every 12 wks)64 (157)7215.84530.1PASI 75/wk 12Ustekinumab 90 mg (wks 0, 4 and every 12 wks)62 (157)7217.34428.7PASI 75/wk 12Placebo31 (157)72164930.3PASI 75/wk 12Leonardi, 2008 \[[@CR30]\]Ustekinumab 45 mg sc (wks 0, 4 and every 12 wks)255 (766)7619.744.820.5PASI 75/wk 12Ustekinumab 90 mg sc (wks 0, 4 and every 12 wks)256 (766)7619.646.219.7PASI 75/wk 12Placebo255 (766)7620.444.820.4PASI 75/wk 12Tsai, 2011 \[[@CR41]\]Ustekinumab 45 mg sc (wks 0, 4 and then every 12 wks)61 (121)2811.940.925.2PASI 75/wk 12Placebo60 (121)2813.940.422.9PASI 75/wk 12Zhu, 2013 \[[@CR44]\]Ustekinumab 45 mg sc (wks 0, 4 and then every 12 wks)160 (332)3214.640.123.2PASI 75/wk 12Placebo162 (332)3214.239.222.7PASI 75/wk 12DrugAuthor, yearIntervention/comparatorNo. of patients achieving PASI 50No. of patients achieving PASI 75No. of patients achieving PASI 90No. of patients achieving PASI 100Prior immunobiologic treatment/concomitant systemic medication^b^AdalimumabAsahina, 2010 \[[@CR22]\]Adalimumab sc (40 mg EOW)^c^282214NDNo/noAdalimumab sc (80 mg wk 0 + 40 mg EOW starting wk 1)352717NDNo/noAdalimumab sc (80 mg EOW)^c^383426NDNo/noPlacebo920NDNo/noGordon, 2006 \[[@CR5]\]Adalimumab 40 mg sc (80 mg wk 0 + 40 mg EOW starting week 1)ND24ND5ND/noAdalimumab 40 mg sc (80 mg wk 0 and 1 + 40 mg/wk starting wk 2)^c^ND40ND13ND/noAdalimumab 40 mg sc (80 mg wk 0 and 1 + 40 mg/wk starting wk 2)^c^ND40ND13ND/noPlaceboND2ND0ND/noGordon 2015 \[[@CR48]\]Guselkumab 200 mg sc (wk 0, 4 and every 12 weeks)^c^ND34241220 (42)/NDGuselkumab 100 mg sc (every 8 weeks)^c^ND33261417 (42)/NDGuselkumab 50 mg sc (wk 0, 4 and every 12 weeks)^c^ND3419815 (42)/NDGuselkumab 15 mg sc (every 8 weeks)^c^ND3114514 (41)/NDGuselkumab 5 mg sc (wk 0, 4 and every 12 weeks)^c^ND1814419 (41)/NDAdalimumab sc (80 mg wk 0 and 1, then EOW)ND30191126 (43)/NDPlaceboND21015 (42)/noMenter, 2008 \[[@CR32]\]Adalimumab 40 mg sc (80 mg wk 0 and 40 mg EOW starting week 1)ND57836616397 (814)/noPlaceboND268453 (398)/noSaurat, 2007 \[[@CR39]\]Adalimumab 40 mg sc (80 mg wk 0 + 40 mg EOW starting wk 1)95865518No/noMethotrexate oral (7.5 mg until 25 mg/wk)^c^6839158No/noPlacebo161061No/noApremilastPapp, 2012 \[[@CR7]\]Apremilast 10 mg orally bid^c^ND10NDNDND/noApremilast 20 mg orally bid^c^ND25NDNDND/noApremilast 3 0 mg orally bidND36NDNDND/noPlaceboND5NDNDND/noPapp, 2015 \[[@CR35]\]Apremilast 30 mg bidND18355ND162 (562)/noPlaceboND141ND80 (282)/noBrodalumabLebwohl, 2015\
 Amagine2 \[[@CR21]\]Brodalumab 210 mg sc EOWND528ND272177 (612)/noBrodalumab 140 mg sc EOWND406ND157179 (610)/noUstekinumabND210ND6584 (300)/noPlaceboND25ND290 (309)/noLebwohl, 2015\
 Amagine3 \[[@CR21]\]Brodalumab 210 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)ND531ND229157 (624)/yesBrodalumab 140 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)ND435ND170160 (629)/yesUstekinumabND217ND5875 (313)/yesPlaceboND19ND176 (315)/yesPapp, 2012 \[[@CR11]\]Brodalumab 70 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)^c^20137416 (39)/noBrodalumab 140 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)3530281510 (39)/noBrodalumab 210 mg sc (wks 0, 1, 2, 4, 6, 8, and 10)3633302517 (40)/noBrodalumab 280 mg sc monthly^c^3428241219 (42)/noPlacebo600016 (38)/noEtanerceptBachelez, 2015 \[[@CR45]\]Tofacitinib 5 mg bid21613069ND35 (330)/noTofacitinib 10 mg bid266210119ND29 (332)/noEtanercept 100 mg/wk269197108ND37 (336)/noPlacebo2261ND12 (108)/noBagel, 2012 \[[@CR23]\]Etanercept sc (100 mg/wk)523716ND6 (62)/noPlacebo431ND7 (62)/noGottlieb, 2003 \[[@CR26]\]Etanercept sc (50 mg/wk)ND17NDNDNo/noPlaceboND1NDNDNo/noGottlieb, 2011 \[[@CR49]\]Etanercept sc (100 mg/wk)ND79NDND20 (141)/noBriakinumab 200 mg sc (wks 0 and 4 then 100 mg wk 8)ND113NDND39 (138)/noPlaceboND5NDND10 (68)/noGriffiths, 2015\
 Uncover-2 \[[@CR46]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^ND31524814284 (347)/yesIxekizumab (160 mg wk 0 and 80 mg every 2 wks)ND26920710785 (351)/yesEtanercept (100 mg/wk)ND149671976 (358)/yesPlaceboND41143 (168)/yesGriffiths, 2015\
 Uncover-3 \[[@CR46]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^ND33626214558 (385)/yesIxekizumab (160 mg wk 0 and 80 mg every 2 wks)ND32525213558 (386)/yesEtanercept (100 mg/wk)ND204982860 (382)/yesPlaceboND146033 (193)/yesLangley, 2014\
 Fixture \[[@CR29]\]Secukinumab 300 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)ND2491757838 (327)/noSecukinumab 150 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)^c^ND2191374745 (327)/noEtanercept sc (100 mg/wk)ND142671445 (326)/noPlaceboND165035 (326)/noLeonardi, 2003 \[[@CR31]\]Etanercept sc (25 mg/wk)^c^65235NDNo/noEtanercept sc (50 mg/wk)945519NDNo/noEtanercept sc (100 mg/wk)1218136NDNo/noPlacebo2461NDNo/noMease, 2000 \[[@CR8]\]Etanercept sc (50 mg/wk)ND5NDNDND/yesPlaceboND0NDNDND/yesPapp, 2005 \[[@CR50]\]Etanercept sc (50 mg/wk)1246620NDNo/noEtanercept sc (100 mg/wk)1479439NDNo/noPlacebo1861NDNo/noStrober, 2011 \[[@CR51]\]Etanercept sc (100 mg/wk)ND551981 (139)/noBriakinumab 200 mg sc (wks 0 and 4, then 100 mg wk 8)ND112774015 (139)/noPlaceboND5303 (72)/noTyring, 2007 \[[@CR42]\]Etanercept sc (100 mg/wk23014665NDND/noPlacebo43153NDND/noVan der Kerkhof, 2008 \[[@CR28]\]Etanercept sc (50 mg/week)663613NDND/noPlacebo411NDND/noInfliximabChaudari, 2001 \[[@CR4]\]Infliximab 5 mg/kg iv (wks 0, 2 and 6)ND9NDNDNo/noInfliximab 10 mg/kg iv (wks 0, 2 and 6)^c^ND8NDNDNo/noPlaceboND2NDNDNo/noGottlieb, 2004 \[[@CR47]\]Infliximab 3 mg/kg iv (wks 0, 2 and 6)837145ND32 (99)/noInfliximab 5 mg/kg iv (wks 0, 2 and 6)968757ND33 (99)/noPlacebo1131ND16 (51)/noMenter, 2007 \[[@CR33]\]Infliximab 3 mg iv (wks 0, 2 and 6)ND220116ND49 (313) NoInfliximab 5 mg iv (wks 0, 2 and 6)ND237142ND45 (314)/noPlaceboND41ND27 (208)/noReich, 2005 \[[@CR38]\]Infliximab 5 mg iv (wks 0, 2, 6, and then every 8 wks)274242172NDNo/noPlacebo621NDNo/noTorri, 2010 \[[@CR40]\]Infliximab 5 mk/kg iv (wks 0, 2, 6 and 8)ND24NDNDND/noPlaceboND0NDNDND/noYang, 2012 \[[@CR43]\]Infliximab 5 mk/kg iv (wks 0, 2, 6, 14 and 22)796848NDND/noPlacebo610NDND/noIxekizumabGriffiths, 2015\
 Uncover-2 \[[@CR46]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^ND31524814284 (347)/yesIxekizumab (160 mg wk 0 and 80 mg every 2 wks)ND26920710785 (351)/yesEtanercept (100 mg/wk)ND149671976 (358)/yesPlaceboND41143 (168)/yesGriffiths, 2015\
 Uncover-3 \[[@CR46]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^ND33626214558/ (385)YesIxekizumab (160 mg wk 0 and 80 mg every 2 wks)ND32525213558 (386)/yesEtanercept (100 mg/wk)ND204982860 (382)/yesPlaceboND146033 (193)/yesGordon, 2016\
 Uncover-1 \[[@CR53]\]Ixekizumab sc (160 mg wk 0 and 80 mg every 4 wks)^c^ND357279145168 (432)/noIxekizumab (160 mg wk 0 and 80 mg every 2 wks)ND386307153173 (433)/noPlaceboND1720181 (431)/noSecukinumabBlauvelt, 2014 \[[@CR24]\]Secukinumab 300 mg sc (wks 0, 1, 2, 3, 4, 8)ND45362523 (59)/noSecukinumab 150 mg sc (wks 0, 1, 2, 3, 4, 8)^c^ND4127528 (59)/noPlaceboND00026 (59)/noLangley, 2014\
 Erasure \[[@CR29]\]Secukinumab 150 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)^c^ND174953173 (245)/noSecukinumab 150 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)^c^ND2191374745 (327)/noPlaceboND113273 (248)/noLangley, 2014\
 Fixture \[[@CR29]\]Secukinumab 300 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)ND2491757838 (327)/noSecukinumab 150 mg sc (wks 0, 1, 2, 3 and 4, then wks 8 and 12)^c^ND2191374745 (327)/noEtanercept sc (100 mg/wk)ND142671445 (326)/noPlaceboND165035 (326)/noPaul, 2014 \[[@CR37]\]Secukinumab 150 mg sc (wks 0, 1, 2, 3, 4, 8)ND44331015 (61)/noSecukinumab 300 mg sc (wks 0, 1, 2, 3, 4, 8)ND53241615 (60)/noPlaceboND20013 (61)/noTofacitinibBachelez \[[@CR45]\]Tofacitinib 5 mg bid21613069ND35 (330)/noTofacitinib 10 mg bid266210119ND29 (332)/noEtanercept 100 mg/wk269197108ND37 (336)/noPlacebo2261ND12 (108)/noPapp, 2012 \[[@CR14]\]Tofacitinib 2 mg orally bidND12NDND10 (49)/noTofacitinib 5 mg orally bidND20NDND15 (49)/noTofacitinib 15 mg orally bidND33NDND10 (49)/noPlaceboND1NDND16 (50)/noPapp, 2015\
 OPT1 \[[@CR52]\]Tofacitinib 5 mg orally bidND14572ND113 (363)/noTofacitinib 10 mg bidND213140ND113 (360)/noPlaceboND111ND53 (177)/noPapp, 2015\
 OPT2 \[[@CR52]\]Tofacitinib 5 mg orally bidND17393ND92 (382)/noTofacitinib 10 mg bidND223148ND97 (381)/noPlaceboND2210ND47 (196)/noUstekinumabIgarashi, 2011 \[[@CR27]\]Ustekinumab 45 mg (wks 0, 4 and every 12 wks)533821ND1 (64)/noUstekinumab 90 mg (wks 0, 4 and every 12 wks)524227NDNo/noPlacebo421NDNo/noLeonardi, 2008 \[[@CR30]\]Ustekinumab 45 mg sc (wks 0, 4 and every 12 wks)21317110632134 (255)/noUstekinumab 90 mg sc (wks 0, 4 and every 12 wks)2201709428130 (256)/noPlacebo26850128 (255)/noTsai, 2011 \[[@CR41]\]Ustekinumab 45 mg sc (wks 0, 4 and then every 12 wks)514130513 (61)/noPlacebo83109 (61)/noZhu, 2013 \[[@CR44]\]Ustekinumab 45 mg sc (wks 0, 4 and then every 12 wks)1461321073819 (160)/noPlacebo32185111 (162)/no*EOW* every other week, *bid* twice daily, *sc* subcutaneous, *iv* intravenous, *ND* not disclosed, *PASI* Psoriasis Area and Severity Index^a^Studies with multiple treatment arms were included more than once in the table^b^Number of patients who received prior biologic or small molecule therapy (total number of patients on study drug)^c^Drugs or doses not included in the final analysis

At FDA-approved dose regimens, 1054 patients were randomized to adalimumab, 650 to apremilast, 2957 to etanercept (535--50 mg/wk, and 2422--100 mg/wk), 844 to infliximab, 1169 to ixekizumab, 691 to secukinumab, and 1678 to ustekinumab (949--45 mg, and 729--90 mg). With regard to drugs still not approved by the FDA, 2554 patients were randomized to brodalumab (1278--140 mg, and 1276--210 mg) and 2197 to tofacitinib (1124--5 mg, and 1073--10 mg).

Considering PASI 75 as the primary endpoint, ixekizumab (160 mg week 0 and 80 mg every 2 weeks) was the drug that achieved the higher RD (0.84, 95% CI 0.81--0.88), followed by brodalumab at a dose of 210 mg (weeks 0, 1, 2, 4, 6, 8, and 10) \[RD 0.79, 95% CI 0.76--0.82). Figure [2](#Fig2){ref-type="fig"} shows the remaining comparisons. Infliximab 5 mg/kg (RD 0.76, 95% CI 0.73--0.79) and secukinumab 300 mg (RD 0.76, 95% CI 0.71--0.81) performed comparably. The overall pooled effect favored treatment when compared with placebo (RD 0.59, 95% CI 0.58--0.60) \[Fig. [3](#Fig3){ref-type="fig"}\]. When analyzing PASI 75 as an outcome, the estimated NNT for ixekizumab, brodalumab 210 mg, infliximab and secukinumab was 1.19, 1.26, 1.31 and 1.31, respectively. A summary of comparisons is reported in Table [2](#Tab2){ref-type="table"}.Fig. 2Meta-analysis (random-effects model) of the Psoriasis Area and Severity Index 75% response rate of biologic and small molecule inhibitor therapies for moderate to severe psoriasis in randomized, placebo-controlled trials. *CI* confidence interval, *M-H* Mantel--Haenszel, *EOW* every other week, *df* degrees of freedom, *bid* twice daily Fig. 3Meta-analysis (random-effects model) of the Psoriasis Area and Severity Index 75% response rate of all treatments combined for moderate to severe psoriasis in randomized, placebo-controlled trials (overall pooled effect). *CI* confidence interval, *M-H* Mantel--Haenszel Table 2Summary of results for drugs and doses sorted by drug classDrug classDrug/dosePASI 75PASI 90PASI 100Primary endpointRD (95% CI)NNTRD (95% CI)NNTRD (95% CI)NNT(weeks)Anti-TNFAdalimumab load (80 mg week 0 + 40 mg week 1) + 40 mg EOW0.62 (0.58--0.67)1.610.43 (0.39--0.46)2.320.18 (0.12--0.24)5.5512--16Etanercept 100 mg/wk0.44 (0.40--0.48)2.270.22 (0.18--0.25)4.540.05 (0.04--0.07)2012Etanercept 50 mg/wk0.31 (0.27--0.35)3.220.10 (0.07--0.13)100.06 (0.01--0.10)16.612Infliximab 5 mg/kg0.76 (0.73--0.79)1.310.53 (0.46--0.60)1.88NDND10Overall pooled effect0.54 (0.47--0.60)1.850.28 (0.21--0.35)3.570.10 (0.04--0.16)10--Anti-IL-12/23Ustekinumab 90 mg0.67 (0.60--0.74)1.490.42 (0.30--0.54)2.380.15 (0.07--0.22)6.6612Ustekinumab 45 mg0.64 (0.60--0.69)1.560.45 (0.35--0.55)2.220.16 (0.10--0.21)6.2512Overall pooled effect0.65 (0.62--0.69)1.530.44 (0.37--0.51)2.270.15 (0.11--0.19)6.66--Anti-IL-17Brodalumab 210 mg0.79 (0.76--0.82)1.260.75 (0.61--0.89)1.330.44 (0.35--0.53)2.2712Brodalumab 140 mg0.64 (0.57--0.70)1.560.72 (0.57--0.86)1.380.26 (0.23--0.30)3.8412Ixekizumab 160 mg week 0 and 80 mg every 2 weeks0.84 (0.81--0.88)1.190.69 (0.65--0.72)1.440.37 (0.35--0.40)2.7012Secukinumab 300 mg0.76 (0.71--0.81)1.310.53 (0.46--0.60)1.880.28 (0.22--0.34)3.5712Overall pooled effect0.76 (0.70--0.82)1.310.61 (0.54--0.68)1.630.35 (0.30--0.40)2.85--Small molecule inhibitors (anti-JAK/anti-PD4)Tofacitinib 10 mg0.53 (0.47--0.58)1.880.36 (0.33--0.39)2.77NDND12Tofacitinib 5 mg0.34 (0.31--0.38)2.940.19 (0.17--0.22)5.26NDND12Apremilast 30 mg bid0.30 (0.23--0.36)3.33NDNDNDND16Overall pooled effect0.43 (0.30--0.55)2.320.27 (0.13--0.42)3.7NDND--*PASI* Psoriasis Area and Severity Index, *RD* risk difference, *CI* confidence interval, *NNT* number needed to treat, *EOW* every other week, *bid* twice daily, *JAK* Janus kinase, *PD4* phosphodiesterase 4, *ND* not determined, *TNF* tumor necrosis factor, *IL* interleukin

When PASI 90 was used as an outcome, both doses of brodalumab---210 mg (RD 0.75, 95% CI 0.61--0.89) and 140 mg (RD 0.72, 95% CI 0.57--0.86---achieved a higher chance of improvement, followed by ixekizumab (RD 0.69, 95% CI 0.65--0.72). Secukinumab and infliximab showed the same RD, with exactly the same CI (RD 0.53, 95% CI 0.46--0.60). The remaining comparisons are reported in Fig. [4](#Fig4){ref-type="fig"}. The overall pooled effect favored treatment in relation to placebo (RD 0.39, 95% CI 0.38--0.40) \[Fig. [5](#Fig5){ref-type="fig"}\].Fig. 4Meta-analysis (random-effects model) of the Psoriasis Area and Severity Index 90% response rate of biologic and small molecule inhibitor therapies for moderate to severe psoriasis in randomized, placebo-controlled trials. *CI* confidence interval, *M-H* Mantel--Haenszel, *EOW* every other week, *df* degrees of freedom, *bid* twice daily Fig. 5Meta-analysis (random-effects model) of the Psoriasis Area and Severity Index 90% response rate of all treatments combined for moderate to severe psoriasis in randomized, placebo-controlled trials (overall pooled effect). *CI* confidence interval, *M-H* Mantel--Haenszel

Brodalumab 210 mg was also the drug that achieved higher RD if PASI 100 was used as the outcome (RD 0.44, 95% CI 0.35--0.53). The approved drugs performed as follows: ixekizumab (RD 0.37, 95% CI 0.35--0.40), secukinumab (RD 0.28, 95% CI 0.22--0.34), adalimumab (RD 0.18, 95% CI 0.12--0.24), and ustekinumab 45 mg (RD 0.16, 95% CI 0.10--0.21). Other comparisons are reported in Fig. [6](#Fig6){ref-type="fig"}. The overall pooled effect of treatment versus placebo was also favorable towards treatment (RD 0.24, 95% CI 0.23--0.25) \[Fig. [7](#Fig7){ref-type="fig"}\].Fig. 6Meta-analysis (random-effects model) of the Psoriasis Area and Severity Index 100% response rate of biologic and small molecule inhibitor therapies for moderate to severe psoriasis in randomized, placebo-controlled trials. *CI* confidence interval, *M-H* Mantel--Haenszel, *EOW* every other week, *df* degrees of freedom Fig. 7Meta-analysis (random-effects model) of the Psoriasis Area and Severity Index 100% response rate of all treatments combined for moderate to severe psoriasis in randomized, placebo-controlled trials (overall pooled effect). *CI* confidence interval, *M-H* Mantel--Haenszel

Heterogeneity (*I* ^2^) on the PASI 75 outcome analysis was below 40% in the following drugs: adalimumab (*I* ^2^ = 13%), apremilast (*I* ^2^ = 34%), brodalumab 210 mg (*I* ^2^ = 0%), etanercept 50 mg (*I* ^2^ = 0%), infliximab (*I* ^2^ = 0%), tofacitinib 5 mg (*I* ^2^ = 0%), and ustekinumab 45 mg (*I* ^2^ = 33%). Moderate heterogeneity was found in the etanercept 100 mg (*I* ^2^ = 59%), secukinumab (*I* ^2^ = 46%), and tofacitinib 10 mg (*I* ^2^ = 58%) groups. In addition, substantial heterogeneity was seen in the following groups: brodalumab 140 mg (I^2^ = 71%), ixekizumab (*I* ^2^ = 64%), and ustekinumab 90 mg (*I* ^2^ = 67%) \[Fig. [2](#Fig2){ref-type="fig"}\]. Heterogeneity for remaining outcomes (PASI 90 and 100) have been reported in Figs. [4](#Fig4){ref-type="fig"} and [6](#Fig6){ref-type="fig"}.

The funnel plot of the PASI 75 outcome did not disclose discrepancies with regard to the magnitude of the effect measured and study size. PASI 90 and PASI 100 funnel plots are not typical, and the lack of symmetry observed may be an indication of publication bias (Online Resource 3, 4, and 5).

Meta-regression was performed to evaluate the contribution of mean baseline PASI, previous use of biologics, and duration of the disease to the heterogeneity among studies (Online Resource 6). None of these variables explained the heterogeneity.

Discussion {#Sec7}
==========

In the present review, anti-IL-17 drugs performed very well. Ixekizumab presented the higher RD in the primary outcome (PASI 75), while brodalumab (210 mg) performed well, following ixekizumab on the primary outcome and achieving a higher RD on both secondary outcomes (PASI 90 and PASI 100). Nevertheless, as the CI overlapped, ixekizumab, brodalumab 210 mg, and secukinumab should be considered as having similar performances, even with different RDs. On the other hand, ixekizumab and brodalumab 210 mg were superior to all remaining drugs, with the exception of infliximab and secukinumab, when PASI 75 was the outcome (no overlapping of the CI).

When analyzing PASI 90 as an outcome, brodalumab (both doses) had the higher RD, but the performance of ixekizumab was similar to the overlapped CI. Nevertheless, it is important to emphasize that only one brodalumab study \[[@CR11]\] (both dosages) could be identified that used PASI 90 as an outcome; however, a low number of patients were enrolled in this study. Therefore, the results regarding brodalumab at this particular outcome should be considered with caution. Ixekizumab was also the best performing drug, and was superior than all the remaining approved medications (no overlapping of the CI). Ixekizumab also showed the highest RD among approved drugs at PASI 100, and was superior to all remaining medications (no overlapping of the CI) when drugs were compared with placebo. At the same outcome, brodalumab 210 mg achieved a higher RD than ixekizumab, but effectiveness was comparable as the CI overlapped. The number of studies included in the analysis of PASI 100 outcome for brodalumab was higher, enrolling more than 1200 patients, which makes these findings more robust than the findings for brodalumab when PASI 90 was analyzed.

Among the newer small molecule inhibitor drugs, tofacitinib, an anti-Janus kinase 1, also performed well at a dose of 10 mg, being superior to lower-dose etanercept when compared with placebo, and comparable to higher-dose etanercept and adalimumab and low-dose brodalumab (overlapping CI), considering PASI 75 as the primary outcome.

On the other hand, apremilast, an anti-phosphodiesterase 4 drug, performed poorly. Nevertheless, it is comparable to low-dose etanercept (50 mg/week) and low-dose tofacitinib (5 mg) at the primary outcome. PASI 90 and 100 analyses could not be performed for apremilast as no studies that could supply the appropriate data were identified.

In accordance with previous meta-analyses \[[@CR16], [@CR52]\], infliximab also performed well among approved biologics. At both dosages (45 and 90 mg), ustekinumab had basically the same performance, which may be explained by the fact that the included studies did not stratify the analysis by patient weight and dosage. The order of effectiveness, measured by RD, in which infliximab 5 mg/kg, ustekinumab 90 mg, ustekinumab 45 mg, adalimumab, etanercept 100 mg, and etanercept 50 mg were positioned in this meta-analysis, was the same as that reported by Schmitt et al. in a recent meta-analysis \[[@CR16]\]. Using a different meta-analysis methodology (Bayesian, network meta-analysis), Reich et al. \[[@CR54]\] identified a similar ranking with regard to the chance of a PASI 75 response, with the exception of the etanercept 100 mg response rate, which was not contemplated in the study. It is important to note that a rank of RD is somewhat deceiving as the CI may overlap. Nevertheless, the concordance of the rank seen in the work of Reich et al., which used a Bayesian analysis, and the RD rank found in this work, indicates a consistent trend \[[@CR54]\].

It is important to emphasize that the objective of this meta-analysis was to compare active treatments against placebo. A limitation to this work is that it is not inherently designed to make indirect comparisons of active treatments and, as previously stated, overlapping CIs determine that drugs are equally effective. A further Bayesian network meta-analysis should be performed to address this issue and, eventually, allow indirect comparisons to rank active treatments.

Considering approved doses and PASI 75 as an outcome, heterogeneity inside each group has been found to be low (*I* ^2^ ≤ 40%) or moderate (*I* ^2^ \>40, ≤60%) \[[@CR20]\] for all comparisons, except for ustekinumab 90 mg (*I* ^2^ = 67%), brodalumab (*I* ^2^ = 71%), and ixekizumab (*I* ^2^ = 64%). The heterogeneity of ustekinumab at a higher dose may be explained by the grouped analysis of populations of different weights (\>100 or \<100 kg). After performing sensitivity analysis, the heterogeneity found in the brodalumab subgroup was found to be due to a phase II study \[[@CR11]\] with a low number of participants; heterogeneity for the brodalumab subgroup decreased to 48% after exclusion of this particular study. No reason was found to account for heterogeneity in the ixekizumab group, neither in meta-regression (Online Resource 6) nor in the sensitivity analysis. Heterogeneity of the pooled overall efficacy of active treatments compared with placebo was high, but this intergroup heterogeneity was expected due to the number of different treatments analyzed and the unit of analysis error. Meta-regression was performed to analyze the impact of PASI score prior to treatment, duration of psoriasis, or previous use of biologic or small molecule inhibitor drugs on heterogeneity. None of the pre-defined variables influenced the results. Random-effects meta-analysis was performed as an attempt to incorporate heterogeneity.

Risk of bias assessment showed a small percentage of high risk of bias categorization among the included studies. On the other hand, 50% of the studies did not explicitly disclose the random sequence generation or allocation concealment (selection bias) well enough, although being categorized as having an unclear risk of bias.

The funnel plot of the primary outcome (PASI 75) was interpreted as being symmetrical and therefore it is less likely that publication bias may have been present. Larger studies are based on the mean RD at the top of the plot. The lack of smaller studies is responsible for the empty space found at the bottom of the plot, but one can assume this is due to the inclusion and exclusion criteria of the systematic review (only placebo-controlled RCTs). Two smaller studies are found on the plot but they are symmetrically positioned on each side of the mean RD. PASI 90 and 100 funnel plot were asymmetric, and both showed smaller studies to be highly efficacious, resulting in a plot that had an empty lower left quadrant. One explanation for this asymmetry is that studies that evaluated less effective drugs may have chosen not to report PASI 90 and 100, while studies evaluating more effective drugs tend to report these outcomes. Therefore, publication bias cannot be ruled out.

The time of outcomes assessment may also be a limitation in the interpretation of the results. As the majority of RCTs used a 12-week timeframe, extrapolation of the results for longer periods may not be appropriate.

Conclusions {#Sec8}
===========

This meta-analysis showed that biologics and small molecule inhibitors are highly effective for the treatment of moderate to severe psoriasis, and that anti-IL-17 drugs have the same, or even greater, efficacy than anti-tumor necrosis factor (TNF) and anti-IL-12/23 drugs when PASI 75 or PASI 90 are used as the outcome. If PASI 100 is used as the outcome, newer drugs such as anti-IL-17 tend to perform better than anti-TNF and anti-IL-12/23 drugs. As the number of newer biologic and small molecule inhibitor drugs increases, the efficacy of these drugs compared with placebo, found in this meta-analysis, can help doctors to choose what the most appropriate treatment is for each particular patient.
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